Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2022 update
• Spotlight

About Prescrire

• Who are we?
• How we work
• AMP: non-profit
• Financing
• No conflicts of interest
• Where to find us
• About Prescrire International
• Testimonials
• Prescrire events
• A global network

Offers

• Subscribe now
• Solidarity Subscription Rate
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

Prescrire's other websites

In Prescrire's Spotlight

Ozanimod (Zeposia°) in multiple sclerosis. As ineffective and probably as toxic as fingolimod FEATURED REVIEW This immunosuppressant has been authorised in the European Union for use in adults with a relapsing-remitting form of multiple sclerosis. Is ozanimod more effective than an interferon beta at reducing the number of relapses and slowing the progression of disability? And what are its adverse effects? Full review (3 pages) available for download by subscribers. 1 May 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ In the May issue of Prescrire International: Pertuzumab + trastuzumab (Phesgo°) by subcutaneous injection, in certain types of breast cancer FREE DOWNLOAD A solution for subcutaneous injection containing a fixed-dose combination of these two anti-HER2 monoclonal antibodies has been authorised in the EU. How do Prescrire's editors rate this combination in its new form? Full text available for free download. 1 May 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ The EMA is withholding too much information  Editorial  Transparency is a requirement for better and safer patient care. There is no valid reason to hide information about clinical trials, their methodology or their results, or evaluation data obtained on drugs after their market introduction, particularly data on adverse effects. 1 May 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ European Medicines Agency: insufficient transparency In Focus The EMA's failings on transparency warrant an official inquiry, so that European decision-makers can take remedial action. 1 May 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ "Preventing Overdiagnosis 2022": an international conference to be held in Calgary, 9-12 June The not-for-profit group "Preventing Overdiagnosis", dedicated to "winding back the harms of too much medicine", will be holding its 2022 conference in Calgary, Canada. 10 May 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Fostemsavir (Rukobia°) in multidrug-resistant HIV-1 infection The initial treatment for patients with HIV-1 infection is based on a combination of antiretroviral drugs. Sometimes the virus is or becomes resistant to the various drug combinations that are available. How do Prescrire's editors rate fostemsavir (Rukobia°) in this situation? 1 May 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Pharmacobezoars may prolong effects of overdose Pharmacobezoars are a possibility to be kept in mind when, after intentional overdose with drugs taken in a solid form, symptoms of overdose persist or reappear after initial improvement. 1 May 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Prescrire's Solidarity Support Programme: facilitating access to reliable and independent information around the world Since 1993, Prescrire's Solidarity Support Programme has been raising funds from Prescrire subscribers, helping health professionals in countries with insufficient financial resources and those training to become healthcare professionals to obtain quality, independent information. The Programme has just published its annual report for 2021. 1 May 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Prescrire's response to public consultation on the revised Guideline on the acceptability of names for human medicinal products  ADVANCING HEALTHCARE POLICY  Prescrire welcomes several of the proposed revisions, but also expressed concerns as regards the correct use of International Non-proprietary Names (INN), and threats to EMA's independence, if the agency becomes involved in negotiations with companies for possible re-use or "conditional acceptability" of names. 1 May 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Covid-19 : Follow Prescrire's independent, evidence-based analysis of the pandemic  COVID-19  Prescrire's editors are publishing an ongoing series of articles featuring independent analysis of developments related to the covid-19 pandemic. Useful and practical information, to help health professionals gain a clear and balanced view. 1 May 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON Peanut allergy: oral desinsitisation with peanut protein • Esketamine in certain types of depression • Messenger RNA covid-19 vaccines during pregnancy • The 2021 finances of Association Mieux Prescrire • Access to clinical study reports should be guaranteed... > Subscribe now 1 May 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International  SUBSCRIBE NOW!  Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 150 euros (less for students and residents of lower-income countries). 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Follow Prescrire International on Facebook and Twitter Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. Click here to > Follow us on Facebook or > Follow us on Twitter 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Watch the video of the webinar "Prescrire, A Critical Eye on New Drugs"  VIDEO  How many new drugs offer an advantage and how many bring nothing new? Prescrire has been answering this key question since 1981. In a March 2022 webinar organised by Consilium Scientific, Pierre Chirac of Prescrire explained the reason for Prescrire's existence, the people behind it, its operations, its main achievements, and its limitations. 21 March 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ "Top Texts of 2021", from the editors of Prescrire International  FREE SPECIAL EDITION  Check out this sampling of texts from Prescrire International, a wholly independent monthly drug bulletin, written by and for healthcare professionals. Inside, top articles from sections dedicated to new drugs authorised in Europe and updates on adverse drug effects, plus our annual update of drugs to avoid. > Click here for your free copy 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Drugs to avoid, in the name of better patient care   DRUGS TO AVOID - 2022 UPDATE  Independent French medical journal Prescrire has published its annual update of drugs to avoid. The goal is to make it easier to choose high-quality care, and to prevent disproportionate harm to patients. > Read more

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Read more All the subjects in Prescrire's Spotlight >

• Sitemap |
• Terms of use |
• Contact
• |Top of page